TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02811406

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Receives IV albumin infusion
Description: IV albumin 20% 50 mL for every 1L of ascitic fluid drained. Blood pressure and heart rate are recorded every four hours in both groups in the first 48 hours.~If hypotension occurs (defined as fall in systolic blood pressure of \> 20 mmHg from baseline) during drainage, drain is clamped and the patient will be clinically evaluated for cause of hypotension. If no other causes of hypotension are found and patient remains asymptomatic, repeat blood pressure measurement in 30 minutes. If blood pressure maintains \> 90/50 mmHg after 30 minutes and patient is asymptomatic, continue drainage and patient stays in the study. If patient remains hypotensive (BP \< 90/50) or develops symptomatic hypotension, then the patient will be taken off study and the hypotension managed as clinically indicated.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Do not receive IV albumin infusion
Description: No IV albumin infusion. Blood pressure and heart rate are recorded every four hours in both groups in the first 48 hours.~If hypotension occurs (defined as fall in systolic blood pressure of \> 20 mmHg from baseline) during drainage, drain is clamped and the patient will be clinically evaluated for cause of hypotension. If no other causes of hypotension are found and patient remains asymptomatic, repeat blood pressure measurement in 30 minutes. If blood pressure maintains \> 90/50 mmHg after 30 minutes and patient is asymptomatic, continue drainage and patient stays in the study. If patient remains hypotensive (BP \< 90/50) or develops symptomatic hypotension, then the patient will be taken off study and the hypotension managed as clinically indicated.
Study: NCT02898077

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered IV
Study: NCT02510898

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 6-week Writing to Heal course
Description: During this 6-week class, a writing-to-heal instructor will coach participants through a simple progression of writing exercises. Participation requires neither any prior writing experience nor any aspiration to become a writer. In fact, the practices cultivate participants' natural abilities to express the ideas that define who they are and how they experience their lives.~Weekly sessions build on previous sessions to provide a progression of experiences for participants to develop their natural styles of writing-to-heal. The instructor will guide participants through a variety of modes of writing that enhance health in different ways.
Study: NCT00626197

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Description: Intravenous and oral repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Description: Intravenous and oral repeating dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Corticosteroids
Description: Intravenous and oral repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide was administered at a IV dose 500 mg every 2 weeks for up to 6 doses followed by maintenance treatment with azathioprine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide was administered at a IV dose 500 mg every 2 weeks for up to 6 doses followed by maintenance treatment with azathioprine.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cyclophosphamide
Description: Cyclophosphamide was administered at a IV dose 500 mg every 2 weeks for up to 6 doses followed by maintenance treatment with azathioprine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Mycophenolate Mofetil was administered orally at maximum dose of 3 g/day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Mycophenolate Mofetil was administered orally at maximum dose of 3 g/day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mycophenolate Mofetil
Description: Mycophenolate Mofetil was administered orally at maximum dose of 3 g/day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocrelizumab
Description: Ocrelizumab was administed at a dose and as per schedule in arm description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocrelizumab
Description: Ocrelizumab was administed at a dose and as per schedule in arm description

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was administered as per schedule in arm description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azathioprine
Description: Azathioprine was administered at a dose up to 2 mg/kg/day with a maximum dose of 200 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azathioprine
Description: Azathioprine was administered at a dose up to 2 mg/kg/day with a maximum dose of 200 mg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Azathioprine
Description: Azathioprine was administered at a dose up to 2 mg/kg/day with a maximum dose of 200 mg.
Study: NCT04333251

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: high-titer anti-Sars-CoV-2 plasma
Description: Recipients will receive 1-2 units of ABO matched donor plasma at neutralization antibody titer \>1:64 vs best supportive care
Study: NCT00611806

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Folic Acid
Description: Folic acid 2mg po daily

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: B12
Description: B12 400 micrograms po daily

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 capsule po daily
Study: NCT00903643

Intervention type: OTHER
Intervention: Physical examination
Description: Physical examination and multiple questionnaires will be administered

Intervention type: OTHER
Intervention: Physical examination
Description: Physical examination and multiple questionnaires will be administered
Study: NCT00631293

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: lactisole
Description: administration of lactisole followed by placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: administration of placebo followed by lactisole
Study: NCT01505777

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probiotics (Medirac)
Description: 10/mosapride 10mg three times a day, P.O. 4week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probiotics (Medirac)
Description: 15/mosapride 10mg three times a day, P.O. 4week
Study: NCT04333251

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: oxygen therapy
Description: oxygen therapy
Study: NCT03605576

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fu's subcutaneous needling
Description: Fu's Subcutaneous Needle (FSN), is an innovation for the treatment of myofascial pain and trigger points. The needle is a non-injection needle, and the fact that both needles are manipulated and act on soft connective tissue.~FSN abstains from the muscle and deep fascia layers and is confined to only the subcutaneous layer where collagen fibers are most abundant. As the subcutaneous layer is poorly innervated, pain is less than other needling therapies.~FSN is also currently being used successfully to treat non-musculoskeletal conditions.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous electrical nerve stimulation
Description: Transcutaneous electrical nerve stimulation (TENS or TNS) is the use of electric current produced by a device to stimulate the nerves for therapeutic purposes.~TENS, by definition, covers the complete range of transcutaneously applied currents used for nerve excitation although the term is often used with a more restrictive intent, namely to describe the kind of pulses produced by portable stimulators used to treat pain. The unit is usually connected to the skin using two or more electrodes. A typical batteryoperated TENS unit is able to modulate pulse width, frequency and intensity. Generally TENS is applied at high frequency (\>50 Hz) with an intensity below motor contraction (sensory intensity) or low frequency (\<10 Hz) with an intensity that produces motor contraction.
Study: NCT02021552

Intervention type: OTHER
Intervention: blood sampling
Description: 5 ml blood sampling
Study: NCT00847067

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Paravertebral block
Description: 3ml 1% Ropivacaine at each level T1 - T5

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham injections
Description: Sham injections with Normal Saline
Study: NCT00864201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bosentan
Description: bosentan 62mg bid x 4 weeks, followed by bosentan 125mg bid x 20 weeks
Study: NCT04100876

Intervention type: GENETIC
Intervention: Global DNA methylation will be quantified in the DNA samples by colorimetry
Description: Global DNA methylation will be quantified in the DNA samples by colorimetry

Intervention type: GENETIC
Intervention: Global DNA methylation will be quantified in the DNA samples by colorimetry
Description: Global DNA methylation will be quantified in the DNA samples by colorimetry
Study: NCT03825731

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GC022
Description: GC022 is a bispecific CAR-T cell immunotherapy that targeted CD19 and CD22. The subjects will receive one dose of GC022 infusion. The dosage ranges from 3×10\^5 to 1×10\^7 CAR+T/Kg.
Study: NCT02651857

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fuse® Colonoscope
Description: Endoscopic diagnostic procedures for lower GI tract

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fuse® Gastroscope
Description: Endoscopic diagnostic procedures for upper GI tract
Study: NCT02126761

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Adjuvanted, trivalent subunit influenza vaccine
Description: Group 1 and group 5 are active comparators; group 5 includes placebo comparator as a second injection in contralateral deltoid

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Adjuvanted, trivalent subunit influenza vaccine
Description: Group 1 and group 5 are active comparators; group 5 includes placebo comparator as a second injection in contralateral deltoid

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adjuvant level modified adjuvanted, trivalent subunit influenza vaccine
Description: Group 2 and group 6 are experimental; group 2 has double dosage of MF59 in a single injection; group 6 has triple dosage of MF59 and includes placebo comparator in contralateral deltoid

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adjuvant level modified adjuvanted, trivalent subunit influenza vaccine
Description: Group 2 and group 6 are experimental; group 2 has double dosage of MF59 in a single injection; group 6 has triple dosage of MF59 and includes placebo comparator in contralateral deltoid

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Antigen level modified adjuvanted, trivalent subunit influenza vaccine
Description: Group 3 is experimental with double the usual antigen dosage

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Antigen and adjuvant level modified adjuvanted, trivalent subunit influenza vaccine
Description: Group 4 and 7 are experimental; group 4 has one injection with double the antigen and adjuvant; group 7 has two injections with double the antigen and adjuvant

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Antigen and adjuvant level modified adjuvanted, trivalent subunit influenza vaccine
Description: Group 4 and 7 are experimental; group 4 has one injection with double the antigen and adjuvant; group 7 has two injections with double the antigen and adjuvant
Study: NCT01057329

Intervention type: DRUG
Intervention: Atomoxetine
Description: mg according to body weight

Intervention type: DRUG
Intervention: Duloxetine
Description: 30 mg / die

Intervention type: DRUG
Intervention: Olanzapine
Description: 5mg 1 wwek and 10 mg from second week

Intervention type: DRUG
Intervention: Aripiprazole
Description: 5 mg from week 1, 10 mg from week 2

Intervention type: DRUG
Intervention: Aripiprazole
Description: 5 mg from week 1, 10 mg from week 2
Study: NCT03167372

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Litebook® Advantage
Description: Standard system light therapy device used in an investigation to assess the feasibility of conducting a randomized trial design. The lightbox produces different wavelengths of the light identical to the peak wavelengths of the sun - bright white, dim white and red light.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Litebook® Advantage
Description: Standard system light therapy device used in an investigation to assess the feasibility of conducting a randomized trial design. The lightbox produces different wavelengths of the light identical to the peak wavelengths of the sun - bright white, dim white and red light.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fitbit Flex2 TM
Description: Standard system activity and sleep tracker

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fitbit Flex2 TM
Description: Standard system activity and sleep tracker
Study: NCT03268447

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus plantarum P8
Description: This project aims to study the benefits of probiotics namely Lactobacillus plantarum P8 for brain health benefits primarily to alleviate stress, among adults in Malaysia aged from 18-60 years.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This project aims to study the benefits of probiotics namely Lactobacillus plantarum P8 for brain health benefits primarily to alleviate stress, among adults in Malaysia aged from 18-60 years.
Study: NCT03896152

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LNP023
Description: approximately 2 year of Treatment with LNP023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LNP023
Description: approximately 2 year of Treatment with LNP023
Study: NCT00615745

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atripla (ATR) consisting of EFV 600 mg/FTC 200 mg/TDF 300 mg
Description: Atripla (ATR) consisting of EFV 600 mg/FTC 200 mg/TDF 300 mg as one tablet orally once daily taken on an empty stomach at bedtime.
Study: NCT02134418

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT of irony comprehension
Description: Over the course of intervention participants will analyze and discuss short film scenario's that end with an ironic statement, and will experience completing short scenario's that contain irony. Intervention will include 5 sessions, each session will take 40 minutes, 3-5 subjects will participate in each group.
Study: NCT03929445

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endotracheal tube introducers
Description: Endotracheal tube introducers (gum elastic bougie) for emergency intubation The endotracheal tube introducer (ETI) is an effective and inexpensive adjunct to difficult airway management that is easy to use.~ETI is solid introducer 60-70 cm long with a 35 - 40 distally angulated (Coude) tip. They are easy to use, widely available, and have been used as adjuncts to difficult direct laryngoscopy for many decades.~The gum elastic bougie is usually guided by tactile clicks as the device passes the cartilage rings of the trachea. After Supraglottic devices are removed, an ETT can subsequently be railroaded over the bougie.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endotracheal tube introducers
Description: Endotracheal tube introducers (gum elastic bougie) for emergency intubation The endotracheal tube introducer (ETI) is an effective and inexpensive adjunct to difficult airway management that is easy to use.~ETI is solid introducer 60-70 cm long with a 35 - 40 distally angulated (Coude) tip. They are easy to use, widely available, and have been used as adjuncts to difficult direct laryngoscopy for many decades.~The gum elastic bougie is usually guided by tactile clicks as the device passes the cartilage rings of the trachea. After Supraglottic devices are removed, an ETT can subsequently be railroaded over the bougie.
Study: NCT02141620

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cocaine
Description: The pharmacodynamic effects of cocaine will be determined during maintenance on placebo and n-acetylcysteine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cocaine
Description: The pharmacodynamic effects of cocaine will be determined during maintenance on placebo and n-acetylcysteine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: n-Acetylcysteine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03183219

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryosurgery or IRE surgery
Description: Cryosurgery or IRE surgery will be used in local tumor

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: γδ T cell
Description: γδ T cells will be used against Liver Cancer

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: γδ T cells/ A Cryosurgery or IRE
Description: Combination γδ T cell and Cryosurgery or IRE surgery will be used in Liver Cancer
Study: NCT01505777

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probiotics (Medirac)
Description: 15/mosapride 15mg three times a day, P.O. 4week
Study: NCT00281515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lonafarnib
Description: 100mg/twice a day during chemotherapie,in maintenance phase 200 mg twice a day

Intervention type: DRUG
Group type: OTHER
Intervention: Lonafarnib
Description: 100mg/twice a day during chemotherapie,in maintenance phase 200 mg twice a day
Study: NCT02478268

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyperpolarized 129-Xenon gas
Description: Hyperpolarized xenon will be administered in multiple doses in volumes up to 25% of subject TLC followed by a breath hold of up to 15 seconds. Subsequent 129Xe doses will only be administered once the subject is ready to proceed.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyperpolarized 129-Xenon gas
Description: Hyperpolarized xenon will be administered in multiple doses in volumes up to 25% of subject TLC followed by a breath hold of up to 15 seconds. Subsequent 129Xe doses will only be administered once the subject is ready to proceed.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MRI
Description: Conventional 1H MRI will be used to provide anatomical reference scans, as well as pulmonary perfusion.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MRI
Description: Conventional 1H MRI will be used to provide anatomical reference scans, as well as pulmonary perfusion.
Study: NCT00741364

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: vitamin D3 (cholecalciferol)
Description: liquid vitamin D solution (vitamin D3 in ethanol) taken daily at one of three possible doses (400, 10000, or 40000 IU/d) for 4-6 weeks prior to radical prostatectomy

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: vitamin D3 (cholecalciferol)
Description: liquid vitamin D solution (vitamin D3 in ethanol) taken daily at one of three possible doses (400, 10000, or 40000 IU/d) for 4-6 weeks prior to radical prostatectomy

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: vitamin D3 (cholecalciferol)
Description: liquid vitamin D solution (vitamin D3 in ethanol) taken daily at one of three possible doses (400, 10000, or 40000 IU/d) for 4-6 weeks prior to radical prostatectomy
Study: NCT02839525

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Omega 3
Description: 3000mg of n-3 oil (2000mg EPA e 1000mg DHA)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Isolate whey protein
Description: 23g of protein of whey protein

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Omega 3 and Isolate whey protein
Description: 3000mg of n-3 oil (2000mg EPA e 1000mg DHA) and 23g of protein of whey protein

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Eccentric exercise
Description: 100 maximal eccentric contractions of knee extensors, divided into 10 sets of 10 repetitions at intervals of 60 seconds between the series

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Eccentric exercise
Description: 100 maximal eccentric contractions of knee extensors, divided into 10 sets of 10 repetitions at intervals of 60 seconds between the series

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Eccentric exercise
Description: 100 maximal eccentric contractions of knee extensors, divided into 10 sets of 10 repetitions at intervals of 60 seconds between the series
Study: NCT01767571

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cephalexin 125 mg/5ml
Description: Reference product 20 ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cephalexin 125 mg/5ml
Description: Reference product 20 ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cephalexin 250mg/5ml
Description: Test product 10 ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cephalexin 250mg/5ml
Description: Test product 10 ml